Filtered By:
Vaccination: Varicella-Zoster Virus Vaccine
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 2051 results found since Jan 2013.
Pole-to-pole involvement of varicella zoster virus reactivation following COVID-19 vaccination
We present a possible link between anti-SARS-CoV-2 virus vaccination and varicella zoster reactivation in these patients and also describe the clinical features, imaging findings including confocal imaging, corneal nerve fiber analysis, and management with detailed discussion.PMID:37203073 | DOI:10.4103/IJO.IJO_2942_22
Source: Herpes - May 19, 2023 Category: Infectious Diseases Authors: Padmamalini Mahendradas Yash Parmar Sai Bhakti Mishra Aditya Patil Ankush Kawali Srinivasan Sanjay Bhujang Shetty Source Type: research
Clinical and Economic Implications of Increasing Access to Herpes Zoster Vaccination Rate in Community Pharmacies
CONCLUSIONS: Community pharmacy-based herpes zoster vaccination was less costly and gained more QALYs and was associated with improved other clinical outcomes in the State of Utah. This study might be used as a model for future evaluations of other community pharmacy-based vaccination programs in the United States.PMID:37207710 | DOI:10.1016/j.japh.2023.05.012
Source: Herpes - May 19, 2023 Category: Infectious Diseases Authors: Alexandre H Watanabe Sajesh K Veettil Lan My Le Elizabeth Bald Casey Tak Nathorn Chaiyakunapruk Source Type: research
Herpes zoster ophthalmicus: frequency and risk factors for developing uncommon ocular manifestations
CONCLUSIONS: The overall frequency of HZO from 2004 to 2021 was 4.2% and has increased annually since 2012. Uncommon ocular manifestations of PCR-verified HZO, mostly comprised of ARN, were more likely to occur in immunosuppressed patients.PMID:37192736 | DOI:10.1016/j.jcjo.2023.04.011
Source: Canadian Journal of Ophthalmology - May 16, 2023 Category: Opthalmology Authors: Aidan A Dmitriev Jamie Odden David Mora-Boellstorff Paul R Kinchington Kathleen Sheridan John A Viehman Danielle Price Stephen Koscumb Oscar Marroquin Jos é-Alain Sahel Regis P Kowalski Vishal Jhanji Marie-H élène Errera Source Type: research
Long-term risk of herpes zoster following COVID-19: A retrospective cohort study of 2 442 686 patients
This study identified 1 221 343 patients with and without COVID-19 diagnoses with matched baseline characteristics. During the 1-year follow-up period, patients with COVID-19 had a higher risk of HZ compared with those without COVID-19 (HR: 1.59; 95% CI: 1.49-1.69). In addition, compared with the control group patients, those with COVID-19 had a higher risk of HZ ophthalmicus (HR: 1.31; 95% CI: 1.01-1.71), disseminated zoster (HR: 2.80; 95% CI: 1.37-5.74), zoster with other complications (HR: 1.46; 95% CI: 1.18-1.79), and zoster without complications (HR: 1.66; 95% CI: 1.55-1.77). Kaplan-Meier curve analysis (log-rank p &l...
Source: Herpes - May 15, 2023 Category: Infectious Diseases Authors: Yi-Chen Chen Chung-Han Ho Ting-Hui Liu Jheng-Yan Wu Po-Yu Huang Ya-Wen Tsai Chih-Cheng Lai Source Type: research
Cost-effectiveness of recombinant zoster vaccine for adults aged ≥50 years in China
CONCLUSIONS: RZV was most likely to be cost-effective in people aged 60-69 years. A slight decrease in vaccine cost would result in RZV being cost-effective in all people aged ≥50 years.PMID:37182556 | DOI:10.1016/j.amepre.2023.05.007
Source: Herpes - May 14, 2023 Category: Infectious Diseases Authors: Minghuan Jiang Xuelin Yao Jin Peng Liuxin Feng Yue Ma Xinke Shi Yu Fang Hai Fang Source Type: research
Correction to: 114. Long-term Protection Against Herpes Zoster (HZ) by the Adjuvanted Recombinant Zoster Vaccine (RZV): Interim Efficacy, Immuno and Safety Results at Approximately 10 Years after Initial Vaccination
Open Forum Infect Dis. 2023 May 11;10(5):ofad251. doi: 10.1093/ofid/ofad251. eCollection 2023 May.ABSTRACT[This corrects the article DOI: 10.1093/ofid/ofac492.].PMID:37180589 | PMC:PMC10172767 | DOI:10.1093/ofid/ofad251
Source: Herpes - May 14, 2023 Category: Infectious Diseases Source Type: research
Cost-effectiveness of recombinant zoster vaccine for adults aged ≥50 years in China
CONCLUSIONS: RZV was most likely to be cost-effective in people aged 60-69 years. A slight decrease in vaccine cost would result in RZV being cost-effective in all people aged ≥50 years.PMID:37182556 | DOI:10.1016/j.amepre.2023.05.007
Source: Herpes - May 14, 2023 Category: Infectious Diseases Authors: Minghuan Jiang Xuelin Yao Jin Peng Liuxin Feng Yue Ma Xinke Shi Yu Fang Hai Fang Source Type: research
Correction to: 114. Long-term Protection Against Herpes Zoster (HZ) by the Adjuvanted Recombinant Zoster Vaccine (RZV): Interim Efficacy, Immuno and Safety Results at Approximately 10 Years after Initial Vaccination
Open Forum Infect Dis. 2023 May 11;10(5):ofad251. doi: 10.1093/ofid/ofad251. eCollection 2023 May.ABSTRACT[This corrects the article DOI: 10.1093/ofid/ofac492.].PMID:37180589 | PMC:PMC10172767 | DOI:10.1093/ofid/ofad251
Source: Herpes - May 14, 2023 Category: Infectious Diseases Source Type: research
Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation?
Aliment Pharmacol Ther. 2023 Jun;57(11):1343-1344. doi: 10.1111/apt.17490.NO ABSTRACTPMID:37161634 | DOI:10.1111/apt.17490
Source: Herpes - May 10, 2023 Category: Infectious Diseases Authors: Fabio Salvatore Macaluso Ambrogio Orlando Source Type: research
Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation? Authors' reply
Aliment Pharmacol Ther. 2023 Jun;57(11):1345-1346. doi: 10.1111/apt.17519.NO ABSTRACTPMID:37161632 | DOI:10.1111/apt.17519
Source: Herpes - May 10, 2023 Category: Infectious Diseases Authors: Freddy Caldera Aaron C Spaulding Mary S Hayney Francis A Farraye Source Type: research
Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data
This study quantifies RZV coverage and assesses predictors for RZV vaccination using a U.S. claims database. Univariate linear regression provided annual prevalence of RZV vaccination and multivariable logistic regression provided ORs and 95% CIs for associations between predictors and RZV vaccination. A total of 4,124,315 individuals (19,080,914 person-years) were included in this study. Since receiving FDA approval for the prevention of HZ, RZV coverage (of at least one dose) has reached approximately 17% within the eligible U.S. population by January 2021, although significant disparities between demographic groups were...
Source: Vaccine - May 7, 2023 Category: Allergy & Immunology Authors: Chad Y Lewis Kunal Mishra Yuwei Sun Samantha J Sechrist Benjamin F Arnold Nisha R Acharya Source Type: research
Corrigendum to "Immune response of C57BL/6J mice to herpes zoster subunit vaccines formulated with nanoemulsion-based and liposome-based adjuvants" Int. Immunopharmacol. 101(Part B) (2021) 108216
Int Immunopharmacol. 2023 May 5:110260. doi: 10.1016/j.intimp.2023.110260. Online ahead of print.NO ABSTRACTPMID:37150708 | DOI:10.1016/j.intimp.2023.110260
Source: International Immunopharmacology - May 7, 2023 Category: Allergy & Immunology Authors: Lei He Bo Sun Yingnan Guo Kunming Yan Dawei Liu Yang Zang Chunlai Jiang Yong Zhang Wei Kong Source Type: research
